This article is an educational review written from an Australian prescriber’s perspective. Trazodone is a prescription-only medicine in Australia. Nothing here replaces an individual consultation with your GP or psychiatrist.
If you are over 30, you probably know the feeling too well. You go to bed exhausted, but your brain refuses to switch off. You wake at 2 or 3 a.m., stare at the ceiling, and worry about work, money, relationships, ageing parents or kids. The next day you are irritable, foggy, anxious and running on empty. Maybe you have tried mindfulness, herbal teas, over-the-counter sedating antihistamines, or even alcohol to fall asleep. Perhaps you have been prescribed a benzodiazepine in the past and you’re worried about dependence, tolerance and memory blunting.
Many Australians in their 30s, 40s, 50s and beyond are caught in a vicious cycle: chronic insomnia feeds low mood and anxiety, and low mood makes sleep even harder. When sleep and mood collapse together, an ordinary selective serotonin reuptake inhibitor (SSRI) may help mood but initially worsen sleep or leave you feeling wired. This is where trazodone deserves a closer look.
Trazodone is a unique serotonergic medicine with strong sleep-promoting properties. It was first developed as an antidepressant, but over decades Australian clinicians have also used low-dose trazodone at night to help with sleep, especially when insomnia is linked to depression, anxiety or chronic stress. The key point: trazodone is not a benzodiazepine. It does not act primarily on the same receptors as diazepam, temazepam or alprazolam, and it is generally considered to have a lower risk of dependence and misuse.
Mechanistically, trazodone blocks certain serotonin receptors and inhibits serotonin reuptake, while also blocking histamine and alpha-adrenergic receptors. The histamine blockade produces sedation, while the serotonergic effects support mood and anxiety. This dual action makes it attractive for people who need help with both sleep and emotional regulation.
In Australia, trazodone is approved by the Therapeutic Goods Administration (TGA). The TGA-approved product information lists major depressive disorder as the primary indication. However, in real-world Australian practice, prescribers often use lower doses at bedtime for insomnia, particularly insomnia with comorbid depression or anxiety. This is an off-label but well-established use recognised in clinical guidelines and prescribing references.
| Item | Details |
|---|---|
| Drug class | Serotonin antagonist and reuptake inhibitor / atypical antidepressant |
| TGA status | Approved prescription medicine in Australia |
| Approved indication | Major depressive disorder |
| Common off-label use | Insomnia, anxiety-related sleep disturbance, adjunctive mood support |
| Usual adult dose for depression | 150–300 mg daily, often divided or with larger night-time dose |
| Low-dose sleep use | 25–100 mg at bedtime, adjusted under medical supervision |
| Onset of sleep effect | Usually 30–60 minutes after night-time dose |
| Most common side effects | Morning drowsiness, dry mouth, dizziness, headache, nausea |
| Serious rare risks | Priapism, orthostatic hypotension, serotonin syndrome, QT prolongation |
For the over-30 patient who is tired of being tired, trazodone offers several practical benefits. It can help you fall asleep and stay asleep without the hangover of older sedatives. It may improve mood and reduce the anxious rumination that keeps you awake. It is not a quick-fix “sleeping pill” in the traditional sense, but rather a medicine that works on the underlying serotonin imbalance while also promoting restorative sleep.
Below are the clinical topics you should understand before discussing trazodone with your doctor.
In older Australians, the rule is start low and go slow. Elderly patients are more sensitive to sedative and blood-pressure-lowering effects. Falls, hip fractures and daytime confusion are real concerns with any sedating medicine. In Australian practice, a very low starting dose of 25–50 mg at night is often used, with slow upward adjustment only if needed. Many older patients respond well to 25–75 mg nightly for sleep and mood support, without needing the full antidepressant dose.
| Age group | Typical starting dose | Maximum commonly used | Key precautions |
|---|---|---|---|
| 65–75 years | 25–50 mg at night | 100–150 mg daily | Monitor orthostatic dizziness, falls risk |
| 75+ years or frail | 25 mg at night | 50–100 mg daily | Review renal/hepatic function, polypharmacy |
Like many antidepressants, trazodone should not be stopped suddenly, especially if you have been taking it for more than a few weeks. Abrupt discontinuation can cause rebound insomnia, irritability, anxiety, sweating or flu-like symptoms. A gradual taper allows your brain to readjust serotonin signalling. A typical Australian approach is to reduce the dose by 25–50 mg every 1–2 weeks, depending on your current dose and how long you have been taking it.
| Current night-time dose | Step 1 | Step 2 | Step 3 | Monitoring |
|---|---|---|---|---|
| 150 mg | 125 mg for 1–2 weeks | 100 mg for 1–2 weeks | 75 mg, then 50 mg, then 25 mg, then stop | Sleep quality, mood, anxiety, withdrawal symptoms |
| 100 mg | 75 mg for 1 week | 50 mg for 1 week | 25 mg for 1 week, then stop | Insomnia rebound, irritability |
| 50 mg | 25 mg for 1 week | Stop | — | Sleep diary, mood diary |
Never alter your dose without medical advice. Your prescriber may suggest a slower taper if you have been on trazodone for years or have a history of discontinuation sensitivity.
For new mothers, the decision to use any medicine while breastfeeding is emotional and high-stakes. Trazodone passes into breast milk in small amounts. The available data are limited, but trazodone is sometimes used during breastfeeding when the mother’s mental health requires it. Untreated severe depression, anxiety or insomnia can harm both mother and baby, impair bonding and reduce milk supply through stress. The benefits of a stable, rested mother often outweigh the small theoretical risk of infant sedation.
| Factor | Consideration |
|---|---|
| Milk transfer | Low levels detected; infant plasma levels usually very low or undetectable |
| Potential infant effects | Sedation, poor feeding, irritability — uncommon but monitor closely |
| Maternal benefit | Improved sleep, mood stability, reduced anxiety, better self-care |
| Clinical approach in Australia | Use lowest effective dose, monitor infant for drowsiness or feeding changes, involve paediatrician if concerned |
If you are breastfeeding or planning to, discuss your individual situation with your GP, psychiatrist or a medicines-in-pregnancy service. Never stop an effective antidepressant abruptly out of fear without a planned conversation.
Sleep paralysis is a frightening experience where you wake but cannot move or speak for seconds to minutes. It is more common in people with disrupted sleep, shift work, stress, narcolepsy or post-traumatic stress disorder. Some patients report sleep paralysis while taking or withdrawing from medications that alter REM sleep.
Trazodone’s association with sleep paralysis is complex. It tends to suppress REM sleep early in the night, which may actually reduce sleep paralysis in some people by stabilising sleep architecture. However, rare case reports describe sleep paralysis or vivid dreams during trazodone initiation or withdrawal. If you have a history of sleep paralysis, tell your doctor. Trazodone may still be useful, but the dose and timing may need adjustment.
In Aboriginal and Torres Strait Islander communities, depression, anxiety, trauma and chronic insomnia are common, driven by social determinants of health, intergenerational trauma, racism and reduced access to culturally safe care. Mental health medicines can help, but they are only one part of healing. Trazodone’s sedative and antidepressant effects may be useful for sleep and mood, but prescribing must be done in partnership with the patient, family and community-controlled health services where possible.
Considerations include:
Trazodone is not a substitute for social support, housing, connection to Country or trauma-informed counselling. It can, however, provide a window of better sleep and mood so that other healing work becomes possible.
Migraine and insomnia frequently travel together, especially in women aged 30–50. Chronic sleep deprivation lowers the migraine threshold. Trazodone’s serotonergic modulation and sleep-restoring effects have led some prescribers to use it as an off-label adjunct in patients with migraine and comorbid insomnia or depression. It is not a first-line migraine preventive like propranolol, candesartan, amitriptyline or anti-CGRP medicines, but it may be a useful option when sleep and mood are major triggers. Some patients report fewer migraine days when their sleep improves. If migraine is your main concern, a neurologist or GP with migraine expertise can help decide whether trazodone fits your overall plan.
Trazodone is not a medicine to buy online or use without supervision. The right action is a structured conversation with a health professional. You can prepare by tracking your sleep, mood, energy and triggers for two weeks, then booking a longer GP appointment. Ask directly: “Could trazodone be appropriate for my sleep and mood, and what are the risks for me?”
If you are in crisis or need support while waiting for an appointment, help is available 24/7 in Australia:
Trazodone may help you reclaim your nights and steady your days, but it works best as part of a comprehensive plan that includes sleep hygiene, physical activity, psychological therapy and regular medical review. If you are over 30, exhausted and wondering whether your sleep and mood can improve, the answer is often yes — with the right assessment, the right medicine and the right support.
Speak to your Australian GP or psychiatrist today about whether trazodone is right for you.